Contact
searchSearch
HMP Global
Login

Myelofibrosis Resource Center

Featured

News
Structural Racism Identified as Key Driver of Survival Disparities in Myelofibrosis
12/12/2025
Lisa Kuhns, PhD, MD
Structural racism, rather than biological differences or treatment patterns, appears to drive survival disparities in myelofibrosis (MF) among minority patients, according to a new multicenter analysis, according to study results published in...
Structural racism, rather than biological differences or treatment patterns, appears to drive survival disparities in myelofibrosis (MF) among minority patients, according to a new multicenter analysis, according to study results published in...
Structural racism, rather than...
12/12/2025
Journal of Clinical Pathways
News
Ruxolitinib Plus ESA or Danazol Maintains Efficacy in Patients With Myelofibrosis Who Have Anemia
10/20/2025
Grace Taylor, MS, MA
A post-hoc analysis of the phase 3b JUMP trial shows that adding erythropoiesis-stimulating agents (ESA) or danazol to ruxolitinib preserves spleen and symptom responses while supporting hemoglobin recovery in patients with myelofibrosis who...
A post-hoc analysis of the phase 3b JUMP trial shows that adding erythropoiesis-stimulating agents (ESA) or danazol to ruxolitinib preserves spleen and symptom responses while supporting hemoglobin recovery in patients with myelofibrosis who...
A post-hoc analysis of the phase...
10/20/2025
Journal of Clinical Pathways
News
Pacritinib Shows Promising Real-World Benefits for Myelofibrosis With Anemia
10/10/2025
Grace Taylor, MS, MA
A real-world data study suggests that pacritinib may improve or stabilize hemoglobin and platelet counts in patients with myelofibrosis, including those with severe anemia, reinforcing its potential utility in cytopenic populations.
A real-world data study suggests that pacritinib may improve or stabilize hemoglobin and platelet counts in patients with myelofibrosis, including those with severe anemia, reinforcing its potential utility in cytopenic populations.
A real-world data study suggests...
10/10/2025
Journal of Clinical Pathways
Conference Coverage
Projected Cost and Time Savings With Pacritinib in Transfusion-Dependent Myelofibrosis
05/30/2025
Juliet Gallagher
An economic analysis of the PERSIST-2 trial, presented at ASCO 2025, suggests that pacritinib may offer significant reductions in both cost and time burden associated with red blood cell (RBC) transfusions in patients with myelofibrosis (MF)...
An economic analysis of the PERSIST-2 trial, presented at ASCO 2025, suggests that pacritinib may offer significant reductions in both cost and time burden associated with red blood cell (RBC) transfusions in patients with myelofibrosis (MF)...
An economic analysis of the...
05/30/2025
Journal of Clinical Pathways
News
Myelofibrosis Symptom Assessment Tool Demonstrates Strong Validity and Reliability in Trials
04/15/2025
Lisa Kuhns, PhD, MD
The Myelofibrosis Symptom Assessment Form Total Symptom Score version 4.0 (MFSAF TSS v4.0) reliably captures the symptom experience of patients with myelofibrosis (MF) and effectively differentiates changes over time, supporting its role as a...
The Myelofibrosis Symptom Assessment Form Total Symptom Score version 4.0 (MFSAF TSS v4.0) reliably captures the symptom experience of patients with myelofibrosis (MF) and effectively differentiates changes over time, supporting its role as a...
The Myelofibrosis Symptom...
04/15/2025
Journal of Clinical Pathways
News
Health Care Burden Associated With Anemia in Ruxolitinib-Treated Myelofibrosis
04/08/2025
Juliet Gallagher
A retrospective analysis using the IQVIA PharMetrics Plus database highlights the clinical and economic burden associated with anemia in patients with myelofibrosis (MF) initiating ruxolitinib.
A retrospective analysis using the IQVIA PharMetrics Plus database highlights the clinical and economic burden associated with anemia in patients with myelofibrosis (MF) initiating ruxolitinib.
A retrospective analysis using...
04/08/2025
Journal of Clinical Pathways
News
Oral JAK2 Inhibitor Offers a Viable Second-Line Treatment for Myelofibrosis, but Challenges Remain
03/13/2025
Lisa Kuhns, PhD, MD
Fedratinib, an oral JAK2 inhibitor, has demonstrated efficacy in treating myelofibrosis (MF), particularly in patients who have failed ruxolitinib therapy, according to a study published in the Blood Cancer Journal.
Fedratinib, an oral JAK2 inhibitor, has demonstrated efficacy in treating myelofibrosis (MF), particularly in patients who have failed ruxolitinib therapy, according to a study published in the Blood Cancer Journal.
Fedratinib, an oral JAK2...
03/13/2025
Journal of Clinical Pathways
News
Ruxolitinib Prior to Transplantation Linked to Better Survival in Myelofibrosis
03/05/2025
Grace Taylor, MS, MA
Pre-transplant use of ruxolitinib may enhance survival outcomes for patients with myelofibrosis undergoing stem cell transplantation.
Pre-transplant use of ruxolitinib may enhance survival outcomes for patients with myelofibrosis undergoing stem cell transplantation.
Pre-transplant use of...
03/05/2025
Journal of Clinical Pathways
News
Momelotinib Offsets Transfusion-Related Burden and Costs in Myelofibrosis Treatment
02/19/2025
Grace Taylor, MS, MA
A study published in Cancer reveals that momelotinib reduces transfusion costs and time burden for patients with myelofibrosis compared to ruxolitinib and best available therapy.
A study published in Cancer reveals that momelotinib reduces transfusion costs and time burden for patients with myelofibrosis compared to ruxolitinib and best available therapy.
A study published in Cancer...
02/19/2025
Journal of Clinical Pathways
News
Study Highlights Momelotinib as a Promising Alternative for Myelofibrosis With Anemia
02/05/2025
Grace Taylor, MS, MA
A real-world study shows that momelotinib effectively improves anemia, reduces symptoms, and controls splenomegaly in patients with myelofibrosis, including those previously treated with other JAK inhibitors.
A real-world study shows that momelotinib effectively improves anemia, reduces symptoms, and controls splenomegaly in patients with myelofibrosis, including those previously treated with other JAK inhibitors.
A real-world study shows that...
02/05/2025
Journal of Clinical Pathways
News
Refining Risk Stratification for Myelofibrosis Using Real-World Data
12/20/2024
Juliet Gallagher
Despite advancements in understanding the molecular basis of myelofibrosis (MF), a rare and complex bone marrow disorder, predicting disease outcomes and tailoring treatments remains challenging. A study published in Cancers used real-world...
Despite advancements in understanding the molecular basis of myelofibrosis (MF), a rare and complex bone marrow disorder, predicting disease outcomes and tailoring treatments remains challenging. A study published in Cancers used real-world...
Despite advancements in...
12/20/2024
Journal of Clinical Pathways

Newsfeed

News
Structural Racism Identified as Key Driver of Survival Disparities in Myelofibrosis
12/12/2025
Lisa Kuhns, PhD, MD
Structural racism, rather than biological differences or treatment patterns, appears to drive survival disparities in myelofibrosis (MF) among minority patients, according to a new multicenter analysis, according to study results published in...
Structural racism, rather than biological differences or treatment patterns, appears to drive survival disparities in myelofibrosis (MF) among minority patients, according to a new multicenter analysis, according to study results published in...
Structural racism, rather than...
12/12/2025
Journal of Clinical Pathways
News
Ruxolitinib Plus ESA or Danazol Maintains Efficacy in Patients With Myelofibrosis Who Have Anemia
10/20/2025
Grace Taylor, MS, MA
A post-hoc analysis of the phase 3b JUMP trial shows that adding erythropoiesis-stimulating agents (ESA) or danazol to ruxolitinib preserves spleen and symptom responses while supporting hemoglobin recovery in patients with myelofibrosis who...
A post-hoc analysis of the phase 3b JUMP trial shows that adding erythropoiesis-stimulating agents (ESA) or danazol to ruxolitinib preserves spleen and symptom responses while supporting hemoglobin recovery in patients with myelofibrosis who...
A post-hoc analysis of the phase...
10/20/2025
Journal of Clinical Pathways
News
Pacritinib Shows Promising Real-World Benefits for Myelofibrosis With Anemia
10/10/2025
Grace Taylor, MS, MA
A real-world data study suggests that pacritinib may improve or stabilize hemoglobin and platelet counts in patients with myelofibrosis, including those with severe anemia, reinforcing its potential utility in cytopenic populations.
A real-world data study suggests that pacritinib may improve or stabilize hemoglobin and platelet counts in patients with myelofibrosis, including those with severe anemia, reinforcing its potential utility in cytopenic populations.
A real-world data study suggests...
10/10/2025
Journal of Clinical Pathways
News
Myelofibrosis Symptom Assessment Tool Demonstrates Strong Validity and Reliability in Trials
04/15/2025
Lisa Kuhns, PhD, MD
The Myelofibrosis Symptom Assessment Form Total Symptom Score version 4.0 (MFSAF TSS v4.0) reliably captures the symptom experience of patients with myelofibrosis (MF) and effectively differentiates changes over time, supporting its role as a...
The Myelofibrosis Symptom Assessment Form Total Symptom Score version 4.0 (MFSAF TSS v4.0) reliably captures the symptom experience of patients with myelofibrosis (MF) and effectively differentiates changes over time, supporting its role as a...
The Myelofibrosis Symptom...
04/15/2025
Journal of Clinical Pathways
News
Health Care Burden Associated With Anemia in Ruxolitinib-Treated Myelofibrosis
04/08/2025
Juliet Gallagher
A retrospective analysis using the IQVIA PharMetrics Plus database highlights the clinical and economic burden associated with anemia in patients with myelofibrosis (MF) initiating ruxolitinib.
A retrospective analysis using the IQVIA PharMetrics Plus database highlights the clinical and economic burden associated with anemia in patients with myelofibrosis (MF) initiating ruxolitinib.
A retrospective analysis using...
04/08/2025
Journal of Clinical Pathways
News
Oral JAK2 Inhibitor Offers a Viable Second-Line Treatment for Myelofibrosis, but Challenges Remain
03/13/2025
Lisa Kuhns, PhD, MD
Fedratinib, an oral JAK2 inhibitor, has demonstrated efficacy in treating myelofibrosis (MF), particularly in patients who have failed ruxolitinib therapy, according to a study published in the Blood Cancer Journal.
Fedratinib, an oral JAK2 inhibitor, has demonstrated efficacy in treating myelofibrosis (MF), particularly in patients who have failed ruxolitinib therapy, according to a study published in the Blood Cancer Journal.
Fedratinib, an oral JAK2...
03/13/2025
Journal of Clinical Pathways
News
Ruxolitinib Prior to Transplantation Linked to Better Survival in Myelofibrosis
03/05/2025
Grace Taylor, MS, MA
Pre-transplant use of ruxolitinib may enhance survival outcomes for patients with myelofibrosis undergoing stem cell transplantation.
Pre-transplant use of ruxolitinib may enhance survival outcomes for patients with myelofibrosis undergoing stem cell transplantation.
Pre-transplant use of...
03/05/2025
Journal of Clinical Pathways
News
Momelotinib Offsets Transfusion-Related Burden and Costs in Myelofibrosis Treatment
02/19/2025
Grace Taylor, MS, MA
A study published in Cancer reveals that momelotinib reduces transfusion costs and time burden for patients with myelofibrosis compared to ruxolitinib and best available therapy.
A study published in Cancer reveals that momelotinib reduces transfusion costs and time burden for patients with myelofibrosis compared to ruxolitinib and best available therapy.
A study published in Cancer...
02/19/2025
Journal of Clinical Pathways
News
Study Highlights Momelotinib as a Promising Alternative for Myelofibrosis With Anemia
02/05/2025
Grace Taylor, MS, MA
A real-world study shows that momelotinib effectively improves anemia, reduces symptoms, and controls splenomegaly in patients with myelofibrosis, including those previously treated with other JAK inhibitors.
A real-world study shows that momelotinib effectively improves anemia, reduces symptoms, and controls splenomegaly in patients with myelofibrosis, including those previously treated with other JAK inhibitors.
A real-world study shows that...
02/05/2025
Journal of Clinical Pathways
News
Refining Risk Stratification for Myelofibrosis Using Real-World Data
12/20/2024
Juliet Gallagher
Despite advancements in understanding the molecular basis of myelofibrosis (MF), a rare and complex bone marrow disorder, predicting disease outcomes and tailoring treatments remains challenging. A study published in Cancers used real-world...
Despite advancements in understanding the molecular basis of myelofibrosis (MF), a rare and complex bone marrow disorder, predicting disease outcomes and tailoring treatments remains challenging. A study published in Cancers used real-world...
Despite advancements in...
12/20/2024
Journal of Clinical Pathways
News
Geographic Distribution Creates Disparities in Access to MM CAR T Care Centers
06/03/2026
Rebecca Amrick
A geospatial analysis of multiple myeloma (MM) chimeric antigen receptor (CAR) T care centers in the US illustrated how uneven distribution of these centers contributes to inequitable access, especially for socially vulnerable and underserved...
A geospatial analysis of multiple myeloma (MM) chimeric antigen receptor (CAR) T care centers in the US illustrated how uneven distribution of these centers contributes to inequitable access, especially for socially vulnerable and underserved...
A geospatial analysis of...
06/03/2026
Journal of Clinical Pathways
News
Bispecific Antibodies Demonstrate Favorable Real-World Outcomes for R/R Follicular Lymphoma
05/29/2026
Rebecca Amrick
Bispecific antibodies demonstrate high efficacy rates and low safety risks when used to treat relapsed or refractory (R/R) follicular lymphoma in real-world settings, indicating their ability to improve patient outcomes.
Bispecific antibodies demonstrate high efficacy rates and low safety risks when used to treat relapsed or refractory (R/R) follicular lymphoma in real-world settings, indicating their ability to improve patient outcomes.
Bispecific antibodies...
05/29/2026
Journal of Clinical Pathways
News
Evolving Treatment Patterns in HCC Reflect Expanding Role of Immunotherapy
05/27/2026
Rebecca Amrick
An overview of evolving treatment patterns for hepatocellular carcinoma (HCC) shows the emergence of several new first-line therapies and the decline of second-line therapies, highlighting efforts to optimize treatment sequencing to improve...
An overview of evolving treatment patterns for hepatocellular carcinoma (HCC) shows the emergence of several new first-line therapies and the decline of second-line therapies, highlighting efforts to optimize treatment sequencing to improve...
An overview of evolving...
05/27/2026
Journal of Clinical Pathways
News
Type 2 Diabetes Prevention May Reduce the Risk of Diffuse Large B-cell Lymphoma and Multiple Myeloma
05/26/2026
Rebecca Amrick
A study looking for associations between type 2 diabetes (T2D) and non-Hodgkin lymphoma instead found a positive link between T2D and the risk of multiple myeloma and diffuse large B-cell lymphoma, suggesting that T2D prevention may reduce...
A study looking for associations between type 2 diabetes (T2D) and non-Hodgkin lymphoma instead found a positive link between T2D and the risk of multiple myeloma and diffuse large B-cell lymphoma, suggesting that T2D prevention may reduce...
A study looking for associations...
05/26/2026
Journal of Clinical Pathways
News
Guideline-Based Pathways Could Streamline Prior Authorization Processes
05/21/2026
Rebecca Amrick
Guideline-based pathways have the potential to decrease administrative burdens by streamlining prior authorization approvals.
Guideline-based pathways have the potential to decrease administrative burdens by streamlining prior authorization approvals.
Guideline-based pathways have...
05/21/2026
Journal of Clinical Pathways
News
Higher Radon Levels Connected to Increased Risk of Ovarian Cancer in Postmenopausal Women
05/21/2026
Rebecca Amrick
An observational study finds that exposure to higher levels of radon could increase the risk of ovarian cancer, opening a possibility for ovarian cancer prevention.
An observational study finds that exposure to higher levels of radon could increase the risk of ovarian cancer, opening a possibility for ovarian cancer prevention.
An observational study finds...
05/21/2026
Journal of Clinical Pathways
News
Improving Geriatric Care for Older Patients With MM
05/20/2026
Rebecca Amrick
Medical professionals have identified key challenges and gaps in care for older patients in North America with multiple myeloma (MM) and made recommendations for improving care and education in geriatric oncology.
Medical professionals have identified key challenges and gaps in care for older patients in North America with multiple myeloma (MM) and made recommendations for improving care and education in geriatric oncology.
Medical professionals have...
05/20/2026
Journal of Clinical Pathways
News
High-Risk Individuals Delay Lung Cancer Screenings Until Eligible Despite Expanded Medicare Access
05/18/2026
Rebecca Amrick
A study of Medicare’s nearly-universal access for people 65 and older shows evidence of patients delaying lung cancer screenings until they are eligible for coverage, raising concerns about health care access and patient outcomes.
A study of Medicare’s nearly-universal access for people 65 and older shows evidence of patients delaying lung cancer screenings until they are eligible for coverage, raising concerns about health care access and patient outcomes.
A study of Medicare’s...
05/18/2026
Journal of Clinical Pathways
News
Dexamethasone Prophylaxis is a Promising Intervention Therapy for Patients With RRMM Receiving Cilta-Cel
05/15/2026
Rebecca Amrick
Dexamethasone prophylaxis shows potential in reducing absolute lymphocyte count (ALC) expansion and mitigating immune-related adverse events for patients with relapsed or refractory multiple myeloma (RRMM) being treated with ciltacabtagene...
Dexamethasone prophylaxis shows potential in reducing absolute lymphocyte count (ALC) expansion and mitigating immune-related adverse events for patients with relapsed or refractory multiple myeloma (RRMM) being treated with ciltacabtagene...
Dexamethasone prophylaxis shows...
05/15/2026
Journal of Clinical Pathways
News
HCC Incidence Higher in Rural Populations Due to Changing Risk Factors and Access Barriers
05/15/2026
Rebecca Amrick
Hepatocellular carcinoma (HCC) incidence and mortality disproportionately affect rural and urban populations, reflecting the need for targeted strategies to improve prevention and access to specialty care.
Hepatocellular carcinoma (HCC) incidence and mortality disproportionately affect rural and urban populations, reflecting the need for targeted strategies to improve prevention and access to specialty care.
Hepatocellular carcinoma (HCC)...
05/15/2026
Journal of Clinical Pathways

Conference Coverage

Conference Coverage
Projected Cost and Time Savings With Pacritinib in Transfusion-Dependent Myelofibrosis
05/30/2025
Juliet Gallagher
An economic analysis of the PERSIST-2 trial, presented at ASCO 2025, suggests that pacritinib may offer significant reductions in both cost and time burden associated with red blood cell (RBC) transfusions in patients with myelofibrosis (MF)...
An economic analysis of the PERSIST-2 trial, presented at ASCO 2025, suggests that pacritinib may offer significant reductions in both cost and time burden associated with red blood cell (RBC) transfusions in patients with myelofibrosis (MF)...
An economic analysis of the...
05/30/2025
Journal of Clinical Pathways
Nikolai Podoltsev video thumbnail.
Videos
Current Treatment Options and Recent Developments in Myelofibrosis
03/27/2024

Featuring Nikolai Podoltsev, MD, PhD

Featuring Nikolai Podoltsev, MD,...
Nikolai Podoltsev, MD, PhD, shares key insights from his session on managing myelofibrosis at ASH 2023 and looks at some of the exciting research on the horizon.
Nikolai Podoltsev, MD, PhD, shares key insights from his session on managing myelofibrosis at ASH 2023 and looks at some of the exciting research on the horizon.
Nikolai Podoltsev, MD, PhD,...
03/27/2024
Journal of Clinical Pathways
Douglas Tremblay, MD
Conference Coverage
Examining Predictors of Emergent Thrombocytopenia After Ruxolitinib Treatment Among Patients With Myelofibrosis
01/03/2024
Douglas Tremblay, MD
At the ASH Annual Meeting, Douglas Tremblay, MD, discussed the prevalence and predictors of emergent thrombocytopenia following ruxolitinib treatment among patients with myelofibrosis.
At the ASH Annual Meeting, Douglas Tremblay, MD, discussed the prevalence and predictors of emergent thrombocytopenia following ruxolitinib treatment among patients with myelofibrosis.
At the ASH Annual Meeting,...
01/03/2024
Oncology
Conference Coverage
The Potential of Pelabresib Plus Ruxolitinib For Treating Patients With Myelofibrosis: The MANIFEST-2 Study
12/08/2023
Grace Taylor, MS, MA
A study by Raajit K. Rampal, MD, PhD, and colleagues investigates the effects of pelabresib + ruxolitinib in patients with myelofibrosis who have not been previously treated with a JAK inhibitor.
A study by Raajit K. Rampal, MD, PhD, and colleagues investigates the effects of pelabresib + ruxolitinib in patients with myelofibrosis who have not been previously treated with a JAK inhibitor.
A study by Raajit K. Rampal, MD,...
12/08/2023
Journal of Clinical Pathways
Conference Coverage
Key Factors Influencing Survival Rates in Patients With Myelofibrosis Undergoing Allogeneic Hematopoietic Stem Cell Transplantation
12/07/2023
Grace Taylor, MS, MA
A study by Helen Ajufo, MD, MS, and colleagues evaluated the impact of clinical and molecular factors on the outcomes of allogeneic hematopoietic stem cell transplantation in patients with myelofibrosis.
A study by Helen Ajufo, MD, MS, and colleagues evaluated the impact of clinical and molecular factors on the outcomes of allogeneic hematopoietic stem cell transplantation in patients with myelofibrosis.
A study by Helen Ajufo, MD, MS,...
12/07/2023
Journal of Clinical Pathways
News
Patient-Reported Quality of Life Analyses From the Phase 3 Momentum Study Compares Momelotiniob vs Danazol for the Treatment of Myelofibrosis
03/02/2023
Marta Rybczynski
A phase 3 study comparing danazol vs momelotinib for the treatment of myelofibrosis (MF) found that momelotinib demonstrated greater improvements in disease-related symptoms, physical function, and health-related quality of life among...
A phase 3 study comparing danazol vs momelotinib for the treatment of myelofibrosis (MF) found that momelotinib demonstrated greater improvements in disease-related symptoms, physical function, and health-related quality of life among...
A phase 3 study comparing...
03/02/2023
Journal of Clinical Pathways
Conference Coverage
Exploring Use of Navitoclax in Conjunction With Ruxolitinib in Patients With MF Who are JAKi-Naïve
01/31/2023
Yvette C. Terrie, BS Pharm, RPh
Findings from a recent study indicated that the combination of navitoclax and ruxolitinib for the treatment of primary or secondary MF among patients who were classified as JAKi-naïve provided promising and suggestive evidence of disease...
Findings from a recent study indicated that the combination of navitoclax and ruxolitinib for the treatment of primary or secondary MF among patients who were classified as JAKi-naïve provided promising and suggestive evidence of disease...
Findings from a recent study...
01/31/2023
Journal of Clinical Pathways
Conference Coverage
Machine Learning Model Beneficial in Predicting Overall Survival in Patients With Myelofibrosis
01/31/2023
Yvette C. Terrie, BS Pharm, RPh
Findings from a recent study indicated that the use of a simple machine learning model known as the AIPSS-MF model was associated with an elevated rate of accuracy with regard to predicting OS in patients with primary and secondary MF,...
Findings from a recent study indicated that the use of a simple machine learning model known as the AIPSS-MF model was associated with an elevated rate of accuracy with regard to predicting OS in patients with primary and secondary MF,...
Findings from a recent study...
01/31/2023
Journal of Clinical Pathways
Conference Coverage
Researchers Present Status of PACIFICA Trial for Treatment of Primary or Secondary Myelofibrosis and Severe Thrombocytopenia
01/31/2023
Yvette C. Terrie, BS Pharm, RPh
At the 64th ASH Annual Meeting, researchers provided information about the multinational, multicenter, randomized, controlled Phase III PACIFICA trial, which aims to gather data to validate the efficacy and safety of pacritinib vs the...
At the 64th ASH Annual Meeting, researchers provided information about the multinational, multicenter, randomized, controlled Phase III PACIFICA trial, which aims to gather data to validate the efficacy and safety of pacritinib vs the...
At the 64th ASH Annual Meeting,...
01/31/2023
Journal of Clinical Pathways
Conference Coverage
Community-Engaged Strategies Reduce Cancer Care Delays and Advance Health Equity
03/27/2026
Hannah Musick
A nationwide, community-engaged cancer care initiative shows that coordinated workflows, patient navigation, and targeted social determinants of health interventions can improve treatment adherence, patient satisfaction, and equity in access...
A nationwide, community-engaged cancer care initiative shows that coordinated workflows, patient navigation, and targeted social determinants of health interventions can improve treatment adherence, patient satisfaction, and equity in access...
A nationwide, community-engaged...
03/27/2026
Journal of Clinical Pathways
Conference Coverage
Targeted Education Improves Cancer Pain Management in Community Hospitals
03/27/2026
Grace Taylor, MS, MA
A brief, National Comprehensive Cancer Network (NCCN)-guided educational session markedly improved hospitalists’ confidence and evidence-based cancer pain management practices in a community hospital setting.
A brief, National Comprehensive Cancer Network (NCCN)-guided educational session markedly improved hospitalists’ confidence and evidence-based cancer pain management practices in a community hospital setting.
A brief, National Comprehensive...
03/27/2026
Journal of Clinical Pathways
Conference Coverage
SEER Analysis Highlights Risk Factors for Advanced DLBCL at Diagnosis
03/27/2026
Grace Taylor, MS, MA
A large SEER-based analysis shows that logistic regression can accurately predict advanced-stage diffuse large B-cell lymphoma (DLBCL) at diagnosis, identifying key demographic and clinical risk factors to guide targeted screening and earlier...
A large SEER-based analysis shows that logistic regression can accurately predict advanced-stage diffuse large B-cell lymphoma (DLBCL) at diagnosis, identifying key demographic and clinical risk factors to guide targeted screening and earlier...
A large SEER-based analysis...
03/27/2026
Journal of Clinical Pathways
Olalekan Oluwole, MD, MBBS
Conference Coverage
Time and Travel Impact of CAR T-Cell vs Bispecific Antibody Therapy for Patients With R/R DLBCL: Real-World Analysis
01/26/2026
Olalekan O. Oluwole
Olalekan Oluwole, MD, MBBS, reported that axi-cel was associated with lower time and travel burden than bispecific antibodies in the third-line or later setting for patients with relapsed/refractory diffuse large b-cell lymphoma.
Olalekan Oluwole, MD, MBBS, reported that axi-cel was associated with lower time and travel burden than bispecific antibodies in the third-line or later setting for patients with relapsed/refractory diffuse large b-cell lymphoma.
Olalekan Oluwole, MD, MBBS,...
01/26/2026
Oncology
Conference Coverage
Daratumumab Maintenance Deepens MRD Negativity After ASCT in Multiple Myeloma
12/22/2025
Juliet Gallagher
Minimal residual disease (MRD) status is an increasingly important prognostic marker in multiple myeloma. New data from the phase 3 AURIGA study, presented at ASH 2025, provide detailed insights into MRD dynamics following autologous stem...
Minimal residual disease (MRD) status is an increasingly important prognostic marker in multiple myeloma. New data from the phase 3 AURIGA study, presented at ASH 2025, provide detailed insights into MRD dynamics following autologous stem...
Minimal residual disease (MRD)...
12/22/2025
Journal of Clinical Pathways
Conference Coverage
Biology-Based Strategies for Managing Iron Toxicity in Hematologic Disorders
12/19/2025
Grace Taylor, MS, MA
New insights into iron biology reveal that continuous suppression of toxic, reactive iron—rather than reduction of total iron stores—is critical for preventing organ damage and improving outcomes across transfusion-dependent hematologic...
New insights into iron biology reveal that continuous suppression of toxic, reactive iron—rather than reduction of total iron stores—is critical for preventing organ damage and improving outcomes across transfusion-dependent hematologic...
New insights into iron biology...
12/19/2025
Journal of Clinical Pathways
News
Lenalidomide Before Apheresis Enhances CAR T-Cell Fitness in Newly Diagnosed Multiple Myeloma
12/19/2025
Grace Taylor, MS, MA
Pre-apheresis lenalidomide significantly improved T-cell fitness and pharmacodynamic activity of idecabtagene vicleucel (ide-cel) in newly diagnosed multiple myeloma (NDMM), according to a KarMMa-2 cross-cohort analysis.
Pre-apheresis lenalidomide significantly improved T-cell fitness and pharmacodynamic activity of idecabtagene vicleucel (ide-cel) in newly diagnosed multiple myeloma (NDMM), according to a KarMMa-2 cross-cohort analysis.
Pre-apheresis lenalidomide...
12/19/2025
Journal of Clinical Pathways
Conference Coverage
High-Risk Features Predict Early Relapse After Cilta-Cel Therapy in Relapsed/Refractory Multiple Myeloma
12/18/2025
Grace Taylor, MS, MA
Cilta-cel continues to deliver high response rates in RRMM, yet early relapse remains a critical challenge. A multicenter analysis across 15 US academic institutions evaluated high-risk disease biology to identify predictors of suboptimal...
Cilta-cel continues to deliver high response rates in RRMM, yet early relapse remains a critical challenge. A multicenter analysis across 15 US academic institutions evaluated high-risk disease biology to identify predictors of suboptimal...
Cilta-cel continues to deliver...
12/18/2025
Journal of Clinical Pathways
Conference Coverage
Intensive Isa-VRDc Regimen Shows Strong Progression-Free Survival in Double-Hit Myeloma
12/17/2025
Hannah Musick
An intensified Isa-VRDc regimen achieved an 88% 18-month progression-free survival rate in newly diagnosed, double-hit multiple myeloma patients in the UK RADAR trial, signaling strong early efficacy in this ultra-high-risk population.
An intensified Isa-VRDc regimen achieved an 88% 18-month progression-free survival rate in newly diagnosed, double-hit multiple myeloma patients in the UK RADAR trial, signaling strong early efficacy in this ultra-high-risk population.
An intensified Isa-VRDc regimen...
12/17/2025
Journal of Clinical Pathways
Conference Coverage
Breakthrough Advances in Immunotherapy Transform Care in Leukemia, Lymphoma, and Myeloma
12/17/2025
Grace Taylor, MS, MA
Immunotherapy advancements across leukemia, lymphoma, and myeloma are reshaping treatment pathways, demonstrating deeper responses, improved survival, and expanding earlier-line options for patients.
Immunotherapy advancements across leukemia, lymphoma, and myeloma are reshaping treatment pathways, demonstrating deeper responses, improved survival, and expanding earlier-line options for patients.
Immunotherapy advancements...
12/17/2025
Journal of Clinical Pathways

Special Reports

Special Report
Advancing a Standardized Economic Framework to Power Oncology Pathways: Methods and Model Development From Phase II of the Predictable Cost of Care Working Group
04/23/2026
Edward Arrowsmith, MD; Alan J. Balch, PhD, MSc; Vishnukamal Golla, MD, MPH; Andrew Hertler, MD, FACP; David Jackman, MD; Olaf Lodbrok, MS, MBA; Lalan Wilfong, MD; Gordon Kuntz; Carole Tremonti, RN, MBA
As cancer therapies expand and costs rise, oncology pathway developers need consistent, transparent methods to compare treatment options beyond drug acquisition costs. Building on Phase I’s consensus on relevant cost domains, the Phase II PCC...
As cancer therapies expand and costs rise, oncology pathway developers need consistent, transparent methods to compare treatment options beyond drug acquisition costs. Building on Phase I’s consensus on relevant cost domains, the Phase II PCC...
As cancer therapies expand and...
04/23/2026
Journal of Clinical Pathways
Special Report
Navigating the Management of Metastatic Colorectal Cancer in the Advanced Treatment Setting: Insights From an Expert Panel
08/15/2025
Tanios Bekaii-Saab, MD, FACP; Stacey Cohen, MD; Marwan Fakih, MD; Anwaar Saeed, MD
Review a special report on the current treatment landscape and unmet needs in metastatic colorectal cancer (mCRC).
Review a special report on the current treatment landscape and unmet needs in metastatic colorectal cancer (mCRC).
Review a special report on the...
08/15/2025
Journal of Clinical Pathways
Special Report
Predictable Cost of Care Model for Treatment Decisions: Working Group Consensus Statements for Metastatic Non-Small Cell Lung Cancer
08/15/2025
Edward Arrowsmith, MD; Vishnukamal Golla, MD, MPH; Rhonda Henschel, MBA; Andrew Hertler, MD, FACP; David Jackman, MD; Gordon Kuntz; Olaf Lodbrok, MS, MBA; Carole Tremonti, RN, MBA; Lalan Wilfong, MD
The Predictable Cost of Care Working Group developed a model that can be used by various entities evaluating the impact of treatment on the total cost of care.
The Predictable Cost of Care Working Group developed a model that can be used by various entities evaluating the impact of treatment on the total cost of care.
The Predictable Cost of Care...
08/15/2025
Journal of Clinical Pathways
Special Report
Navigating the Management of Metastatic Colorectal Cancer in the Advanced Treatment Setting: Insights From an Expert Panel
06/12/2025
Tanios Bekaii-Saab, MD, FACP; Stacey Cohen, MD; Marwan Fakih, MD; Anwaar Saeed, MD
Review a special report on the current treatment landscape and unmet needs in metastatic colorectal cancer (mCRC).
Review a special report on the current treatment landscape and unmet needs in metastatic colorectal cancer (mCRC).
Review a special report on the...
06/12/2025
Journal of Clinical Pathways
Page 1
Special Report
Predictable Cost of Care Model for Treatment Decisions: Working Group Consensus Statements for Metastatic Non-Small Cell Lung Cancer
02/19/2025
Edward Arrowsmith, MD; Vishnukamal Golla, MD, MPH; Rhonda Henschel, MBA; Andrew Hertler, MD, FACP; David Jackman, MD; Gordon Kuntz; Olaf Lodbrok, MS, MBA; Carole Tremonti, RN, MBA; Lalan Wilfong, MD
The Predictable Cost of Care Working Group developed a model that can be used by various entities evaluating the impact of treatment on the total cost of care.
The Predictable Cost of Care Working Group developed a model that can be used by various entities evaluating the impact of treatment on the total cost of care.
The Predictable Cost of Care...
02/19/2025
Journal of Clinical Pathways
JCP Special Report
Recommendations for Creating an Oncology Clinical Pathways Framework Tool Based on Payer, Provider, and Patient Priorities: Findings From the 2021 Care Pathways Working Group
05/20/2022
Robin T. Zon, MD, FACP, FASCO; Gordon Kuntz; Winston Wong, PharmD
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways...
05/20/2022
Journal of Clinical Pathways

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use